Holen Sie sich die Stockscreener-App
477.91
0.79%
3.74
Handel nachbörslich:
477.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$474.17
Offen:
$474.09
24-Stunden-Volumen:
1.09M
Relative Volume:
0.77
Marktkapitalisierung:
$121.25B
Einnahmen:
$11.74B
Nettoeinkommen (Verlust:
$3.68B
KGV:
33.68
EPS:
14.1888
Netto-Cashflow:
$3.34B
1W Leistung:
+3.64%
1M Leistung:
+3.24%
6M Leistung:
+3.71%
1J Leistung:
+8.45%
1-Tages-Spanne:
$469.50
$479.50
1-Wochen-Bereich:
$458.31
$485.00
52-Wochen-Spanne:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Barclays Upgrades Vertex Pharmaceuticals (VRTX) with Increased P - GuruFocus
Here’s Why Hardman Johnston Global Equity Strategy Sold Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Barlow Wealth Partners Inc. Sells 21,078 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Physician Views Results: Vertex's Journavx impresses in acute pain, as case for chronic comes into focus - FirstWord Pharma
VRTX Stock Surges 6.1% With A 5-day Winning Spree On Analyst Upgrades - Trefis
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Leader With 8% Potential Upside - DirectorsTalk Interviews
Vertex Pharmaceuticals (VRTX) Sees Price Target Increase by UBS to $545 | VRTX Stock News - GuruFocus
Best Biotech Stocks To Follow NowJanuary 26th - MarketBeat
Vertex Pharmaceuticals price target raised to $545 from $535 at UBS - TipRanks
Lbp Am Sa Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
UniSuper Management Pty Ltd Has $8.03 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AMF Tjanstepension AB Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Analyst Upgrades And CASGEVY Approval - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $10.88 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
How Evolving Analyst Assumptions Are Reshaping The Story For Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Resona Asset Management Co. Ltd. Sells 4,351 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jennison Associates LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Strs Ohio Has $31.58 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Breaking Down Vertex Pharmaceuticals: 12 Analysts Share Their Views - Benzinga
Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It? - Finviz
Vertex Pharmaceuticals (VRTX) Sees Raised Price Target by Everco - GuruFocus
Teacher Retirement System of Texas Sells 3,725 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Up 30%, Analyst Upgrades to Outperform with $546 Target - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Inogen (INGN) - The Globe and Mail
Cystic Fibrosis Therapeutics Market to Reach US$35.09 Billion - openPR.com
RBC Capital Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
FDA Grants Orphan Status to Vertex Pharmaceuticals' (VRTX) Treat - GuruFocus
Vertex Pharmaceuticals (VRTX) Upgraded on Strong Cystic Fibrosis Franchise - GuruFocus
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil - CNBC
Vertex Pharma Stock Is Quietly Going Off – But Is It Actually Worth Your Money? - AD HOC NEWS
RBC Capital Upgrades Vertex Pharmaceuticals (VRTX) Rating to 'Ou - GuruFocus
Vertex Pharma upgraded at RBC Capital Markets citing upside in 2026 - Seeking Alpha
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Outperform at Royal Bank Of Canada - MarketBeat
Boston Common Asset Management LLC Sells 5,164 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Neuropathic Pain Market to Reach US$ 18.45 Billion by 2033 at 8.9% - openPR.com
Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)? - Yahoo Finance
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
Responsibility | Grants and Giving - Vertex Pharmaceuticals
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wealth Enhancement Advisory Services LLC - MarketBeat
Rakuten Investment Management Inc. Makes New $94.96 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bailard Inc. - MarketBeat
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) - The Globe and Mail
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Americana Partners LLC Buys 12,134 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.61%
4.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):